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Epstein-Barr Virus–induced Molecule 1 Ligand Chemokine Is
Expressed by Dendritic Cells in Lymphoid Tissues and
Strongly Attracts Naive T Cells and Activated B Cells
 
By Vu N. Ngo, H. Lucy Tang, and Jason G. Cyster
 
From the Department of Microbiology and Immunology, University of California at San Francisco, San 
Francisco, California 94143-0414
 
Summary
 
Movement of T and B lymphocytes through secondary lymphoid tissues is likely to involve
multiple cues that help the cells navigate to appropriate compartments. Epstein-Barr virus–
induced molecule 1 (EBI-1) ligand chemokine (ELC/MIP3
 
b
 
) is expressed constitutively
within lymphoid tissues and may act as such a guidance cue. Here, we have isolated mouse
ELC and characterized its expression pattern and chemotactic properties. ELC is expressed
constitutively in dendritic cells within the T cell zone of secondary lymphoid tissues. Recom-
binant ELC was strongly chemotactic for naive (L-selectin
 
hi
 
) CD4 T cells and for CD8 T cells
and weakly attractive for resting B cells and memory (L-selectin
 
lo
 
) CD4 T cells. After activation
through the B cell receptor, the chemotactic response of B cells was enhanced. Like its human
counterpart, murine ELC stimulated cells transfected with EBI-1/CC chemokine receptor 7
(CCR7). Our findings suggest a central role for ELC in promoting encounters between recir-
culating T cells and dendritic cells and in the migration of activated B cells into the T zone of
secondary lymphoid tissues.
Key words: chemokine • dendritic cells • lymphoid tissue • T zone • lymphocyte
A
 
key function of secondary lymphoid tissues is to bring
together antigen, antigen-presenting cells, and rare an-
tigen-specific lymphocytes so that an immune response can
be mounted. Antigen-bearing dendritic cells (DCs)
 
1
 
 drain
into lymphoid tissues from peripheral sites of infection, mi-
grate into the T cell–rich zone, and present antigen on sur-
face MHC molecules (1–3). Naive T cells enter lymphoid
tissues from the blood and spend several hours migrating
through the T zone, making contact with multiple DCs
before returning to circulation. A successful recognition
event between a T cell and an antigen-presenting DC leads
to T cell retention and activation (3, 4). Resting B cells en-
ter lymphoid tissues through the same pathways as T cells
but rapidly home into B cell–rich microenvironments,
 
lymphoid follicles, where they reside for 
 
z
 
12 h before re-
turning to circulation (5, 6). The tropism of B cells is al-
tered markedly upon binding antigen, with the cells relo-
cating to the outer T zone (7, 8). Localization of B cells in
the outer T zone may play an important role in promoting
encounter between antigen-specific B and T cells. The fac-
tors regulating this highly orchestrated movement of cells
within the T zone and between T zone and follicles have
been poorly defined, but several recent studies indicate an
important role for chemokines and chemokine receptors (9).
Chemokines constitute a family of chemotactic cyto-
kines that are subdivided based on the number and spacing
of NH
 
2
 
-terminal cysteines into C, CC, CXC, and CXXXC
chemokines (10–12). The majority of chemokines that have
been shown to attract lymphocytes (e.g., RANTES [for
regulated upon activation, normal T cell expressed and se-
creted], macrophage-inflammatory protein [MIP]1
 
a
 
, mono-
cyte chemoattractant protein [MCP]-1) preferentially at-
tract activated or memory cells and are unlikely to play a
central role in guiding naive T or B lymphocytes through
secondary lymphoid tissues (13–15). However, over the last
year, several new chemokines have been identified that are
constitutively expressed within secondary lymphoid tissues
and that strongly attract naive, resting lymphocytes, including
secondary lymphoid tissue chemokine (SLC)/6C-kine/exo-
dus-2/thymus-derived chemotactic agent 4 (16–20), stromal
cell–derived factor (SDF)1
 
a
 
/pre–B cell growth-stimulating
 
1
 
Abbreviations used in this paper:
 
 BLC, B lymphocyte chemoattractant;
BLR, Burkitt’s lymphoma receptor; CCR, CC chemokine receptor; DC,
dendritic cell; DCCK, dendritic cell–derived CC chemokine; EBI-1,
EBV-induced molecule 1; ELC, EBI-1 ligand chemokine; EF, elongation
factor; EST, expressed sequence tag; HEV, high endothelial venules;
MCP, monocyte chemoattractant protein; MIP, macrophage-inflamma-
tory protein; PARC, pulmonary and activation–regulated chemokine;
RT, reverse transcription; SDF, stromal cell–derived factor; SLC, second-
ary lymphoid tissue chemokine.
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factor (21–23), dendritic cell–derived CC chemokine
(DCCK)1/pulmonary and activation–regulated chemokine
(PARC) (24, 25), and B lymphocyte chemoattractant (BLC)/
B cell–attracting chemokine (BCA)-1 (26, 27). SLC has
been found to strongly attract naive T cells and to more
weakly attract B cells. SLC is expressed by high endothelial
venules (HEV) in LNs and Peyer’s patches and at lower
levels by other cells in the T zone of spleen, LNs, and
Peyer’s patches (17). These properties suggest SLC plays a
role in promoting lymphocyte passage across HEV and en-
try into the T cell region of lymphoid tissues. SDF1
 
a
 
 plays
a critical role in B cell and myeloid cell development (28).
SDF1
 
a
 
 is an efficacious attractant of mature lymphocytes
(17, 23) and of pre-B cells (29), and in a recent study, has
been found expressed in reticular cells located outside ger-
minal centers in human tonsil, suggesting a role in lympho-
cyte trafficking to this site (30). DCCK1 or PARC is ex-
pressed by DCs within germinal centers of human tonsil
and LN that may either be follicular DCs (25) or germinal
center DCs (24). Expression in T zone DCs was reported
in tonsil (24) but not LNs, and no expression was detected
in spleen (25). Since DCCK1 attracts T cells, it may play a
role in promoting DC–T cell interactions (24, 25). BLC/
BCA-1 is a recently defined chemokine expressed by stro-
mal cells within the follicles of secondary lymphoid tissues
that strongly attracts resting B cells but few other cell types
(26, 27). BLC is a ligand for Burkitt’s lymphoma receptor
(BLR)1, a receptor required for B cell homing to follicles
in spleen and Peyer’s patches (31), and this chemokine is
likely to play a key role in promoting the compartmentaliza-
tion of B cells into follicles (26).
ELC (also called MIP3
 
b
 
) is another CC chemokine that
is highly expressed in lymphoid tissues. Expression analysis
of human ELC has identified LNs and appendix as espe-
cially rich sources (32, 33). Expression is also high in hu-
man thymus, whereas expression in spleen is either low
(32) or negative (33). Among various cell populations
tested, monocytes activated by LPS and IFN-
 
g
 
 in the pres-
ence of IL-10–blocking antibodies were the only cells that
expressed significant amounts of ELC (33).
The only receptor characterized to date for ELC, EBV-
induced molecule 1 (EBI-1) or CC chemokine receptor
(CCR)7 (32), was first identified as a molecule upregulated
in EBV-transformed Burkitt’s lymphoma cells (34). The
gene was later isolated from CD4 T cells that had been in-
fected with herpesvirus (35) and by PCR as a molecule ho-
mologous to BLR1 (36). Northern blot analysis demon-
strated that CCR7 is expressed in several B and T cell lines
but not on monocytic or myeloid cell lines or cells of non-
lymphoid origin. Freshly isolated PBLs show measurable
CCR7 mRNA expression, and this can be upregulated by
treatment with phorbol ester, PHA, or anti-CD3 (36).
The expression of ELC within secondary lymphoid tis-
sues and the expression of its receptor CCR7 in lympho-
cytes suggests that ELC may function as a lymphocyte
chemoattractant, perhaps promoting cell compartmental-
ization within these tissues. However, the only cell type
that has been described to date to respond chemotactically
 
to ELC is the T cell lymphoma line HUT78 (32). We re-
port here the identification of mouse ELC, and demon-
strate that this CCR7 ligand is a potent chemoattractant for
resting and acutely activated lymphocytes. Furthermore,
we find that mouse ELC is expressed in DCs in the T cell
zone of LNs, spleen, and Peyer’s patches.
 
Materials and Methods
 
Clone Identification and Sequence Analysis.
 
BLAST searches of
the National Center for Biological Information expressed se-
quence tag (EST) database using human ELC as a query retrieved
contiguous mouse ESTs for ELC. IMAGE Consortium (LLNL)
cDNA clones 1088818 and 77575 were obtained from Genome
Systems, Inc. (St. Louis, MO) as EcoR1-Not1 inserts in the
pT7T3-Pac vector, and sequenced.
 
RNA Expression Studies.
 
For Northern blot analysis, 10–15
 
m
 
g of total RNA from mouse tissues or purified cells was sub-
jected to gel electrophoresis, transferred to Hybond N
 
1
 
 mem-
branes (Amersham Corp., Arlington Heights, IL), and probed us-
ing randomly primed 
 
32
 
P-labeled mouse ELC EST 1088818,
which spans bases 1–755 of the ELC cDNA. To control for load-
ing and RNA integrity, membranes were stripped and reprobed
with a mouse elongation factor (EF)-1
 
a 
 
probe. For in situ hy-
bridizations, frozen sections (5 
 
m
 
m) from C57BL/6 mice were
treated as described (26). In brief, sections were fixed in 4%
paraformaldehyde, washed in PBS, prehybridized for 1–3 h, and
hybridized overnight at 60
 
8
 
C with sense or antisense digoxige-
nin-labeled riboprobes in hybridization solution. After washing at
high stringency, sections were incubated with sheep antidigoxi-
genin antibody (Boehringer Mannheim Biochemicals, Indianapo-
lis, IN) followed by alkaline phosphatase–coupled donkey anti–
sheep antibody (Jackson Immunoresearch Labs, West Grove, PA)
and developed with nitroblue tetrazolium/5-bromo-4-chloro-3-
indoyl phosphate (NBT/BCIP). Immunohistochemistry with
anti-CD3, anti-B220, and anti-CD11c (PharMingen, San Diego,
CA), anti-DEC205 (kindly provided by R. Steinman, Rocke-
feller University, NY), and MOMA-1 (kindly provided by G.
Kraal, Free University, Amsterdam, The Netherlands) antibodies
was as described (37). Reverse transcription (RT)-PCR analysis
of RNA from purified cell populations was with an Advantage
 
TM
 
RT-for-PCR kit (Clontech, Palo Alto, CA) using a mixture of
primers specific for ELC (5
 
9
 
 primer, ggtgctaatgatgcggaagac; and
3
 
9
 
 primer, agacacagggctccttctggt) and hypoxanthine-guanine
phosphoribosyl transferase (5
 
9
 
 primer, cctgctggattacatcaaagcactg;
and 3
 
9
 
 primer, tccaacacttcgtggggtcct).
 
Production of Recombinant ELC.
 
Sequence encoding amino ac-
ids 26–108, which are predicted to encompass mature mouse
ELC based on comparison with the signal peptide cleavage site of
human ELC (32), was isolated by PCR and subcloned into
Nde1-Xho1 sites of the pET23b vector (Novagen, Inc., Madi-
son, WI) in-frame with the COOH-terminal HIS
 
6
 
-tag. TAP302
cells (kindly provided by Tracy Handel, University of California,
Berkeley, CA) were transformed with the vector, the HIS-tagged
chemokine was purified using NiNTA agarose (QIAGEN, Inc.,
Chatsworth, CA) according to the manufacturer’s instructions,
and elution was with 250 mM imidazole (Fisher Scientific Co.,
Pittsburgh, PA). Further purification was achieved using a C-18
reverse-phase HPLC column (Vydac, Hesperia, CA) and elution
with an acetonitrile gradient. SDS-PAGE of this preparation
showed a single band of the expected molecular mass for ELC
(
 
z
 
9 kD) that represented 
 
.
 
90% of the total protein. Protein
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concentration was measured using a protein assay (Bio-Rad Lab-
oratories, Hercules, CA).
 
Cell Purification.
 
B cells were purified by staining non-B
cells with anti–CD43-biotin (PharMingen) and depletion using
streptavidin-MACS
 
Ò
 
 beads and a MACS
 
Ò
 
 (Miltenyi Biotec, Inc.,
Auburn, CA). T cells were purified by staining B cells, macro-
phages, and granulocytes with biotinylated antibodies to B220,
Mac-1, and Gran-1 (PharMingen) and depletion by MACS
 
Ò
 
, ex-
cept for the RT-PCR analysis where T cells were isolated by
positive selection for CD3 (Caltag Laboratories, Inc., South San
Francisco, CA) by MACS
 
Ò
 
. DCs used as a source of RNA for
Northern blotting were purified as described (38). In brief, spleen
or LN suspensions were prepared in RPMI containing 10% FCS,
10 mM Hepes, and antibiotics and adjusted with sodium chloride
to mouse osmolarity (39) by gently pressing through a 70-
 
m
 
M
mesh cell strainer (Fisher Scientific Co.). The suspension was lay-
ered on 2 ml of metrizamide (14.5% by weight in the same me-
dium) solution (Accurate Chemical and Science Corp., West-
bury, NY) and spun at 600 
 
g
 
 for 10 min, and the cells at and
above the interface were isolated. Flow cytometry confirmed that
 
z
 
70% of the cells were CD11c
 
1
 
 DCs. For RT-PCR analysis, in
addition to isolation from cell suspensions as above, DCs were
purified from the tissue fragments that did not go into suspension
by digesting in collagenase D (Boehringer Mannheim Biochemi-
cals) at 1.6 mg/ml and bovine pancreas DNAse (Sigma Chemical
Co.) at 100 
 
m
 
g/ml for 30 min at room temperature. EDTA was
then added to a concentration of 10 mM for 5 min (40), and the
digested preparation was mashed through a cell strainer. Cells were
then stained with antibodies to B220, TcR, and CD11c (PharMin-
gen) and purified to 
 
.
 
93% CD11c
 
1
 
B220
 
2
 
TcR
 
2
 
 by sorting on
a FACStar plus
 
Ò
 
 (Becton Dickinson, San Jose, CA).
 
Chemotaxis.
 
Cell suspensions were prepared from spleen,
LNs, thymus, or bone marrow of C57BL/6 mice as described (8).
In the case of spleen and bone marrow, red blood cells were lysed
using Tris-ammonium chloride. Chemotaxis assays were per-
formed as described (23) using 10
 
6
 
 total cells per 5-
 
m
 
M transwell
(Corning Costar Corp., Acton, MA). Cells that migrated to the
lower chamber were enumerated by collecting events for a fixed
time (60 s) on a FACScan
 
Ò
 
. By counting a 1:5 dilution of input
cells in the same way, the absolute number of cells that transmi-
grated could be determined. To determine which subsets of cells
were migrating, a fraction of the cells that migrated to the lower
chamber was stained and analyzed by flow cytometry. Cells from
resting and activated spleen were stained with B220-FITC (clone
6B2), CD4-PE and CD8-PE (Caltag Laboratories, Inc.), and
L-selectin–biotin/streptavidin cychrome (PharMingen). Migrating
thymocytes were stained with CD8-FITC, CD4-PE (Caltag Labo-
ratories, Inc.), and CD3-biotin (PharMingen), and bone marrow
cells were stained with IgD
 
b
 
-FITC (PharMingen), B220-PE, and
IgM-biotin (Caltag Laboratories, Inc.). Granulocytes were identi-
fied by their characteristic large side scatter. For macrophage
chemotaxis assays, spleen cells were first depleted of B220
 
1
 
,
CD4
 
1
 
, and CD8
 
1
 
 cells by MACS
 
Ò
 
 (Miltenyi Biotec, Inc.), and
migrating cells were identified with Mac-1–PE (Caltag Laborato-
ries, Inc.). In some experiments, cells were preactivated by incu-
bation with phorbol-12,13-dibutyrate (PDBu, 100 ng/ml; Cal-
biochem Corp., San Diego, CA), 17 
 
m
 
g/ml polyclonal anti–mouse
IgM (Jackson ImmunoResearch Labs), or 20 
 
m
 
g/ml LPS. Synthetic
human SDF1
 
a
 
 (N33A) synthesized by chemical ligation (a gift
from M. Siani, Gryphon Sciences, South San Francisco, CA) was
used as a control. This SDF1
 
a
 
 preparation maximally attracts
lymphocytes, macrophages, and granulocytes at 100–500 ng/ml
(26) and therefore was used at 300 ng/ml in these studies.
 
Mouse EBI-1 Transfection and Calcium Fluorimetry.
 
Mouse EBI-1
(41) was isolated by RT-PCR using a 3
 
9
 
 primer downstream of
the stop codon and a 5
 
9
 
 primer starting at amino acid 26 of the
full-length protein, truncating the hydrophobic NH
 
2
 
-terminal
(possible leader) peptide. Both primers contained Sal-1 sites, and
the PCR product was cloned into a modified form of pREP4
(Invitrogen Corp., San Diego, CA) that contains an NH
 
2
 
-termi-
nal prolactin leader sequence and FLAG epitope followed by an
in-frame Sal-1 site (42) (provided by S. Coughlin, University of
California, San Francisco, San Francisco, CA). Human embryonic
kidney 293 cells were transiently transfected with this construct us-
ing LipoTAXI according to the manufacturer’s instructions (Strat-
agene Inc., La Jolla, CA). EBI-1 surface expression 2 d after trans-
fection was confirmed by flow cytometry with anti-FLAG
antibody M2 (VWR Scientific Products, West Chester, PA). Cal-
cium mobilization studies were performed on Indo-1–loaded cells
as described (43) using a spectrometer (model 4500; Hitachi Ltd.,
Tokyo, Japan). Intracellular calcium concentrations were calculated
using the Hitachi 4500 intracellular cation measurement program.
 
Results
 
Identification of Murine ELC Homologue.
 
To permit the
expression pattern and chemotactic activity of mouse ELC
to be studied, we searched for ESTs that may encode
mouse ELC using human ELC as the query sequence (32).
Seven mouse ESTs were identified in the GenBank EST
database (EST nos. 1088818, 906750, 885418, 1183472,
775758, 807269, and 822508) that could be aligned into a
755-bp contig encoding a predicted protein of 108 amino
acids. The high nucleotide sequence identity (84%) and
amino acid identity (78%) of this sequence with human
ELC (Fig. 1) strongly suggested that we had identified
mouse ELC. The proteins with greatest homology to both
mouse and human ELC are mouse and human SLC (Fig.
1). A major difference between ELC and SLC is the ex-
tended cysteine-containing COOH-terminal region unique
to SLC. When this region is excluded from the compari-
son, ELC and SLC are 33% identical. The next closest
match to ELC is MIP3
 
a
 
 (33), with 23% identity. The sim-
ilarity between mouse and human ELC and SLC, together
with the observation that the human genes colocalize on
chromosome 9 (16, 32), is consistent with the possibility
that these molecules arose from a gene-duplication event,
and suggests they may have related functions.
 
ELC Is Expressed in T Cell Zones of Secondary Lymphoid
Tissues.
 
Northern blotting analysis revealed that mouse
ELC was constitutively expressed at high levels in both
mesenteric and peripheral LNs (Fig. 2). Significant expres-
sion was also identified in spleen and Peyer’s patches, and
low expression was seen in the thymus (Fig. 2). No expres-
sion was detected in bone marrow or in several nonlym-
phoid tissues (Fig. 2). To determine whether ELC was pro-
duced by a restricted set of cells within lymphoid tissues,
which might suggest a role in controlling cell positioning,
in situ
 
 
 
hybridization analysis was performed (Fig. 3). Strik-
ingly, the ELC probe hybridized strongly to a subset of
cells within the T cell zone (or periarteriolar lymphatic
sheath) of spleen but not to cells in the B cell follicles or the
 184
 
Mouse ELC Expression and Chemotactic Activity
 
red pulp (Fig. 3 
 
A
 
). Within LNs, ELC-expressing cells
were distributed evenly throughout the T zone (or para-
cortex) and were absent from follicles (Fig. 3 
 
B
 
). Similarly,
in Peyer’s patches, a hybridization signal was detected in
the T cell region (the interfollicular zone) but not within
follicles or in the subepithelial dome region (Fig. 3 
 
C
 
). No
hybridization signal to T zones of secondary lymphoid tis-
sues was seen with a control (sense) probe (Fig. 3 
 
I
 
).
 
ELC Is Expressed by Dendritic Cells.
 
The distribution of
ELC-expressing cells in spleen, LNs, and Peyer’s patches
appeared similar to the distribution of T zone DCs in these
tissues (3). To further investigate this similarity, spleen sec-
tions serial to those used for hybridization were stained to
detect T cells (Fig 3. 
 
D
 
, 
 
red
 
) or with antibodies to CD11c
(44) to detect DCs (Fig. 3 
 
E
 
, 
 
red
 
). These sections were also
stained with antibody to the marginal metallophilic mac-
rophage marker, MOMA-1 (45), to outline the white pulp
cords (Fig. 3, 
 
D 
 
and 
 
E
 
, 
 
brown
 
). The distribution of ELC-
positive cells (Fig. 3 
 
A
 
) was very similar to the distribution
of CD11c
 
1
 
 DCs located in the T zone (Fig. 3, 
 
A
 
,
 
 D
 
,
 
 
 
and
 
E
 
). Interestingly, although clusters of CD11c
 
1
 
 DCs were
also located in the bridging channels between T zone and
red pulp (Fig. 3 
 
E
 
) as observed previously (3, 44), little
ELC hybridization signal was detected in these regions
(Fig. 3, 
 
A 
 
and
 
 E
 
). Staining of a further serial section with
the DC marker DEC205 that is expressed most highly on
DCs in the T zone (3, 46) revealed a close concordance be-
tween the ELC hybridization pattern and the distribution
of DEC205-expressing cells (Fig. 3, 
 
A 
 
and 
 
F
 
). Combined
staining for the fixation-resistant marker B220 and for ELC
confirmed that the ELC-expressing cells were distributed
across the T cell zone but did not extend into the B cell
area of the splenic white pulp (Fig. 3 
 
G
 
). Close examina-
tion of the ELC hybridization signal in the T zone showed
that many of the cells had a striking dendritic morphology
(Fig. 3 
 
H
 
).
To directly test whether DCs were a source of ELC,
Northern blot analysis was performed with RNA from par-
tially purified spleen and LN DCs (Fig. 4 
 
A
 
). ELC expres-
sion was detected in the DC preparations, whereas purified
B cells, T cells, and macrophages did not express detectable
amounts of ELC (Fig. 4 
 
A
 
). To rule out the possibility that
the Northern blot signal derived from a small population of
contaminating cells, CD11c
 
1
 
 splenic DCs were FACS
 
Ò
 
sorted, and ELC expression was measured by RT-PCR. In
agreement with the Northern blot result, ELC expression
was detected in the purified DCs but was undetectable in
purified T cells, B cells, or macrophages (Fig. 4 
 
B
 
). It was
anticipated that if DCs were the major ELC-expressing
cells in the spleen, the PCR signal in the sorted DCs would
be increased compared with the unsorted spleen prepara-
tion, and this is what was observed (Fig. 4 
 
B
 
). Taking the
findings from the in situ hybridization, Northern blot, and
RT-PCR analysis together, we conclude that DCs present
within the T zone are the major source of ELC in second-
ary lymphoid tissues.
 
ELC Strongly Attracts T Cells and Weakly Attracts B
Cells.
 
To characterize the chemotactic properties of mouse
ELC, a COOH-terminal HIS-tagged version was expressed
in 
 
Escherichia coli
 
 and purified to 
 
.
 
90% by affinity- and
high-pressure liquid chromatography. In migration assays
with mouse spleen cells, a strong response was identified in
CD4 and CD8 T cells (Fig. 5 
 
A
 
). Interestingly, CD4 cells
were reproducibly found to be more sensitive to low ELC
concentrations than CD8 cells (Fig. 5 A). B cells showed a
weaker chemotactic response to ELC than both CD4 and
CD8 T cells (Fig. 5 A). Strikingly, CD4 T cells of a naive
(L-selectinhi) phenotype showed a stronger migratory re-
sponse than CD4 T cells of a postactivation or memory
(L-selectinlo) phenotype (Fig. 5 B). Lymphocytes from
blood and LNs showed a similar response as cells from the
spleen (data not shown).
Activated Lymphocytes Have an Enhanced Chemotactic Re-
sponse to ELC. The ELC receptor was identified origi-
Figure 1. Mouse ELC sequence and alignment with human ELC and
SLC. (A) Nucleotide and deduced amino acid sequence of mouse ELC.
The predicted signal sequence is underlined, cysteines are shown in bold,
and a single potential N-linked glycosylation site is underlined. (B) Align-
ment of mouse ELC (mELC) protein sequence with those of human ELC
(hELC) and mouse and human SLC (mSLC and hSLC). Identical amino
acids are shown as hyphens, and dots represent gaps inserted for optimum
alignment. Numbering is with respect to the first amino acid shown in
the full-length protein. These sequence data are available from EMBL/
GenBank/DDBJ under accession no. AF059208.
Figure 2. Northern blotting
analysis of ELC expression in
mouse tissues. Top, Hybridiza-
tion with ELC probe. Bottom,
Hybridization with EF-1a to
control for amounts of RNA
loaded.
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Figure 3. In situ hybridization analysis of ELC expression pattern in mouse lymphoid tissues. (A–C and G–I) Bright-field micrographs showing hy-
bridization with digoxigenin-labeled antisense (A–C, G, and H) or sense (I) ELC probe to sections of spleen (A and G), mesenteric LN (B, H, and I), and
Peyer’s patch (C). Signal is seen as black staining. (D–F) Immunohistochemistry of spleen sections serial to A to detect in brown MOMA-1–positive mar-
ginal metallophilic macrophages (D and E) and in red CD31 T cells (D), CD11c-expressing DCs (E) and DEC205-expressing DCs (F). The spleen sec-
tion in G was double stained to detect B220 (brown) and ELC (black). T, T zone; F, follicle; RP, red pulp; EP, epithelium. Original magnifications: A–F
and I, 35 objective; G, 310 objective; and H, 340 objective.
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nally as a molecule upregulated in EBV-transformed B cells
(34). Other studies indicated that CCR7 is also upregulated
by treatment of PBLs with phorbol ester, PHA, or anti-
CD3 (35, 36). In preliminary experiments with cells cul-
tured overnight in phorbol ester, we observed an increase
in the magnitude of the B cell response to ELC (data not
shown). This experiment encouraged us to test whether
more physiological stimuli also increased B cell responsive-
ness. This was of particular interest because after engage-
ment by antigen in vivo, B cells migrate rapidly into the
outer T zone (7, 8). Cells activated through the B cell re-
ceptor by pretreatment with anti-IgM for 4–6 h showed a
1.5-fold increase in the magnitude of their response to ELC
(Fig. 5, C and D). Similar findings were made using puri-
fied B cells (Fig. 5 E), confirming that this effect was B cell
intrinsic. Activation of B cells in vivo by LPS treatment
also promotes migration of some cells into the T zone (47),
and LPS activation was also found to enhance the B cell
chemotactic response to ELC (Fig. 5 E). The increased
ELC responsiveness of activated B cells did not simply re-
flect an overall increase in B cell motility, as there was little
difference in the frequency of activated and resting cells
that migrated in the absence of chemokine (Fig. 5, C–E).
Furthermore, the activated cells did not demonstrate in-
creased responsiveness to SDF1a (Fig. 5, C–E), indicating
that the enhanced response was ELC specific.
ELC Responsiveness of Thymocytes and Immature B Cells.
Since ELC expression was also detected in the thymus (Fig.
2), the chemotactic response of thymocytes was measured
(Fig. 6). Mature single positive thymocytes responded to
ELC similarly to mature T cells in the periphery (Fig. 6 A),
whereas immature (CD42CD82 double negative) thy-
mocytes and most CD4/CD8 double positive thymocytes
did not show a measurable response (Fig. 6 B). Interest-
ingly, however, when the responding cells were stained
with anti-CD3 antibodies, an enrichment of CD3-bright
CD4/CD8 double positive cells was detected in the popu-
lation that migrated in response to ELC (Fig. 6 B), indicating
that the most mature fraction of double positive cells had
acquired responsiveness to ELC. We also measured the ELC
responsiveness of immature B lineage cells in the bone mar-
row. B2201IgM2IgD2 pre-B cells and B2201IgM1IgD2
immature B cells showed a similar dose-dependent migra-
tory response towards ELC as mature B cells (Fig. 6 C),
indicating that the cells acquire responsiveness to this
chemokine early in development. Consistent with the fail-
ure to detect CCR7 expression in myeloid cells (34, 41),
bone marrow granulocytes (Fig. 6 D) and spleen mono-
cytes/macrophages (Fig. 6 E) did not respond to ELC.
Murine ELC Stimulates Murine CCR7–transfected Cells.
The migration response of lymphocytes to mouse ELC was
chemotactic since the cells failed to migrate when incu-
bated in ELC in the absence of a gradient (Fig. 5 F), and
the pertussis toxin sensitivity of the response (Fig. 5 F) in-
Figure 4. ELC expression in puri-
fied cells. (A) Northern blot analysis
of ELC expression in MACSÒ -puri-
fied spleen B cells and T cells, mouse
peritoneal macrophages (Mac.), and
spleen (Spl.) and LN DCs purified to
z70%. EF-1a hybridization is
shown to control for amounts of
RNA loaded. (B) RT-PCR analysis
of ELC expression in total spleen be-
fore sorting (Spl.) and in splenic
CD11c1 DCs isolated by FACSÒ
sorting (Spl. DC), and lack of ex-
pression in purified spleen B cells
and T cells and peritoneal macro-
phages (Mac.). Primers specific for
HPRT were included in each sam-
ple as a reaction control.
Figure 5. Chemotactic activity of ELC on resting and acutely activated
mouse lymphocytes. Results are expressed as the percentage of input cells
of each subtype migrating to the lower chamber of a transwell filter. Pan-
els show migration of spleen lymphocyte subsets: (A) CD4 T cells, CD8
T cells, and B cells; (B) L-selectinhi and L-selectinlo CD4 T cells; (C) B
cells preincubated with anti-IgM (17 mg/ml) or media alone (control) for
4 h; (D) duplicate experiment to C with cells preincubated with media
alone (2) or anti-IgM (am) for 4 h; (E) purified B cells preincubated with
media alone (2), anti-IgM at 17 mg/ml (am), or LPS at 20 mg/ml (L) for
6 h; (F) total spleen cells in the absence of a gradient (no gradient, equal
concentration of ELC in upper and lower chamber) or preincubated with
pertussis toxin at 200 ng/ml (PTX) for 2 h. In A–E, SDF1a was included
at 300 ng/ml as a positive control. In D, ELC was at 200 ng/ml, and in E
and F at 300 ng/ml. The results in A–C are representative of three inde-
pendent experiments, and results in D–F of two experiments.
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dicated the expected involvement of a Gi-coupled recep-
tor. To test whether the mouse homologue of human ELC
we had identified was a ligand for mouse CCR7/EBI-1, 293
cells were transiently transfected with a FLAG epitope–
tagged form of the receptor and assayed for mouse ELC re-
sponsiveness. CCR7-expressing cells (Fig. 7 A) showed a
rapid rise in intracellular calcium in response to ELC but
not to two other CC chemokines, MIP1a and MCP1 (Fig
7 B). The response of the transfected cells was dose sensi-
tive (Fig. 7 C), and exposure to high dose ELC fully desen-
sitized the cells to further ELC exposure (Fig. 7 B). ELC
did not stimulate a calcium flux in 293 cells transiently
transfected with BLR1, showing that the response of
CCR7-transfected cells to ELC was specific (Fig. 7 D).
These results establish that mouse ELC can stimulate cells
through mouse CCR7/EBI-1.
Discussion
In this report, we have identified mouse ELC and demon-
strated that this CCR7 ligand is highly expressed by interdig-
itating DCs in the T zone of secondary lymphoid tissues.
ELC strongly attracts resting T cells and more weakly attracts
B cells. However, acute activation increases B cell respon-
siveness to ELC. These findings suggest two major roles for
ELC: (a) to attract naive T cells into the T zone of lymphoid
tissues and promote T cell–DC encounters, and (b) to attract
antigen-binding B cells into the T zone of lymphoid tissues.
T and B lymphocytes enter LNs and Peyer’s patches by
crossing HEV located predominantly in the T zone (6, 48).
Lymphocyte attachment to HEV involves chemokine-
induced activation of integrin-mediated adhesion (49). The
physiologically relevant chemokine on HEV that mediates
integrin activation has not been defined, but recent studies
demonstrated that SLC, SDF, and ELC could each pro-
mote integrin-mediated arrest of human lymphocytes in in
vitro rolling chambers (17, 50). The high expression of
SLC by HEV cells (17) together with our failure to detect
ELC expression by HEV (Fig. 3) suggests that SLC may
play the more prominent role in triggering lymphocyte ad-
hesion to HEV. Whether SDF is expressed by HEV has not
yet been well characterized, and its importance at this site
remains to be established. Once lymphocytes have attached
to HEV, they then migrate rapidly into the T zone. Our
finding that ELC is highly expressed by T zone DCs and
that ELC attracts naive lymphocytes suggests that this
chemokine plays an important role in attracting cells away
from HEV into the T zone and into contact with DCs. In-
terestingly, ELC and SLC have a strikingly similar chemo-
taxis profile, since both molecules attract naive T cells more
efficiently than memory cells, and attract B cells more
weakly than T cells. In this regard, it is interesting to note
that SLC is the closest homologue of ELC (Fig. 1) and that
both chemokines colocalize on chromosome 9 (16, 32),
whereas most other CC chemokines cluster on chromo-
some 17 (11). We are currently investigating the possibility
that SLC is also a ligand for CCR7/EBI-1. Since SLC is
expressed at highest levels by HEV and at lower levels by
stromal cells in the T zone (17), this chemokine may be in-
efficient at attracting cells into the T zone once they have
crossed HEV. The existence of DC-derived ELC gradients
may facilitate their movement away from the HEV and in
amongst the T zone DCs. A further chemokine, PARC/
DCCK1, that is expressed by DCs in germinal centers and
Figure 6. Chemotactic activity of ELC on immature T
and B cells and lack of activity on granulocytes and mac-
rophages. Results are expressed as the percentage of input
cells of each subtype migrating to the lower chamber of a
transwell filter. Panels show response of (A) mature CD4 and
CD8 single positive (SP) thymocytes; (B) immature CD4/CD8
double negative (DN) thymocytes, total CD4/CD8 double
positive (DP) thymocytes, and CD3hi double positive thy-
mocytes; (C) bone marrow B2201IgM2IgD2 cells (pre-B),
B2201IgM1IgD2 cells (immature B), and B2201IgM1IgD1
cells (mature B); (D) bone marrow granulocytes; and (E)
spleen macrophages. Insets in A and C show flow cytometric
profiles of input cells and gates used to measure the fre-
quency of each cell type. The profile in C has already been
gated for B2201 cells. The inset in B shows the gate used to
identify high CD3 expression on double positive thymocytes
and, as an example, the fraction of CD3hi double positive
cells that migrated in the absence of ELC or in response to 1
mg/ml ELC. In D and E, SDF1a (300 ng/ml) is included as
a positive control. Each experiment was performed a mini-
mum of two times.
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possibly also T zone DCs, and that can attract naive T cells
(24, 25), may work with ELC to promote naive T cell–DC
encounters. However, in contrast to the concentrated ex-
pression of ELC in secondary lymphoid tissues in humans
(32) and mice (Figs. 2 and 3), PARC/DCCK1 is expressed
at highest levels in the lung (25), suggesting distinct roles
for the two molecules.
Lymphocytes enter the spleen by a different route to LNs
or Peyer’s patches, being released in the marginal sinus that
surrounds the white pulp, or at terminal arterioles in the red
pulp, and then migrating into the T zone (5, 52). However,
as with entry into LNs, entry into the lymphoid region of
the spleen is pertussis toxin sensitive (53, 54), implicating the
involvement of chemokines. The expression of ELC in DCs
within the splenic T zone indicates that ELC is likely to play
a similar role in spleen and LNs, attracting lymphocytes into
the T zone and promoting T cell encounter with DCs. In-
terestingly, despite the absence of HEV in the spleen, SLC
expression is also detected in stromal cells in the splenic T
zone (17), suggesting that these two chemokines may again
act in concert to attract cells into the T zone.
The responsiveness of single positive thymocytes to ELC
is likely to be important in ensuring that when these cells
leave the thymus, they can enter into the T zone of sec-
ondary lymphoid tissues and interact with DCs. Whether
ELC plays a role in thymocyte movement within the thy-
mus is less clear. The expression level of ELC in mouse
thymus was low, and we were unable to obtain a reproduc-
ible in situ hybridization signal (data not shown). However,
the acquisition of ELC responsiveness by mouse thy-
mocytes at the CD3hi, CD4/CD8 double positive stage
suggests ELC may have a role in cell positioning within the
mouse thymus. In this regard, ELC may function with sev-
eral other chemokines identified recently in this tissue (20,
55–59), to help compartmentalize the cells appropriately
for each developmental/selection event. Interestingly, ELC
appears to be expressed at much higher levels in human
thymus (32, 33), suggesting a more prominent role for
ELC in human T cell development.
The weak but significant responsiveness of resting B cells
to ELC is consistent with the original finding of EBI-1/
CCR7 expression in B lymphocytes (34). Previous studies
have shown SLC also weakly attracts resting B cells (17),
and it seems likely that ELC and SLC work together to
promote migration of B cells into the T zone after they
have crossed HEV or entered the marginal sinus of the
spleen. Once in the T zone, the B cells may then enter the
gradient of BLC that attracts the cells into follicles (26). In-
terestingly, immature B cells which do not express BLR1
(60, 61) are able to migrate into the T zone of the spleen
but fail to enter follicles (62, 63). Positioning within the T
zone may play an important role in the maturation or se-
lection of these cells (63). Since immature B cells in the
bone marrow are responsive to ELC (Fig. 6 C), it is reason-
able to propose that once these cells leave the marrow and
enter peripheral lymphoid tissues (especially the spleen), they
are able to migrate into the T zone along a gradient of ELC.
Upon binding antigen, the migration of mature recircu-
lating B cells is altered dramatically. Rather than moving
into follicles, the cells accumulate within 6–8 h in the outer
T zone (7, 37). This repositioning is likely to be critical for
antigen-specific B and T cells to find each other. One
mechanism by which antigen-engaged B cells might relo-
cate to the outer T zone is through increased responsive-
ness to T zone–expressed chemokines. Our finding that
stimulating cells through the antigen receptor increased the
B cell response to ELC raises the possibility that ELC may
participate in recruiting antigen-engaged B cells to this site.
In summary, our findings suggest a central role for ELC
in secondary lymphoid tissue function. The high expres-
sion by T zone DCs and the strong chemotactic activity for
naive T cells suggest that ELC attracts T cells into the T
zone and promotes T cell–DC encounters. The weaker re-
sponsiveness of both immature and mature B cells supports
a role for ELC in attracting these cells into the T zone as
the necessary first step before they migrate into follicles,
whereas the enhanced response of activated B cells impli-
cates ELC as an important cue that promotes localization of
antigen-engaged cells in the T cell zone. Understanding
the factors that regulate ELC expression by DCs and the
signals that control ELC responsiveness of lymphocytes is
likely to teach us much about how secondary lymphoid tis-
sues function in immunity.
Figure 7. Mouse CCR7/EBI-1 mediated calcium mobilization in re-
sponse to ELC. (A) Flow cytometric analysis of FLAG-tagged CCR7 ex-
pression on HEK293 cells transiently transfected with CCR7 expression
vector (Flag-CCR7) compared with cells stained without primary anti-
body (Control). (B) Calcium flux of CCR7-expressing cells in response to
mouse ELC (1 mg/ml) but not MIP1a (0.2 mg/ml) or MCP1 (0.2 mg/ml).
(C) Calcium flux of CCR7-expressing cells as a function of ELC concen-
tration. (D) Lack of response of BLR1-transfected HEK293 cells to ELC
(1 mg/ml). BLC (2 mg/ml) was used as positive control.
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